 | Up a level |
Mark, Michael; Froesch, Patrizia; Gysel, Katrin; Rothschild, Sacha I; Addeo, Alfredo; Ackermann, Christoph J; Chiquet, Sabrina; Schneider, Martina; Ribi, Karin; Maranta, Angela Fischer; Bastian, Sara; von Moos, Roger; Joerger, Markus; Früh, Martin (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European journal of cancer, 200(113600), p. 113600. Elsevier 10.1016/j.ejca.2024.113600
